KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Deferred Taxes (2016 - 2019)

Arbutus Biopharma (ABUS) has disclosed Deferred Taxes for 5 consecutive years, with -$12.7 million as the latest value for Q3 2019.

  • Quarterly Deferred Taxes fell 195.68% to -$12.7 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was -$12.7 million through Dec 2020, up 25.27% year-over-year, with the annual reading at -$12.7 million for FY2019, 195.68% down from the prior year.
  • Deferred Taxes hit -$12.7 million in Q3 2019 for Arbutus Biopharma, down from -$4.3 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of -$989000.0 in Q4 2015 to a low of -$64.9 million in Q2 2016.
  • Historically, Deferred Taxes has averaged -$23.2 million across 5 years, with a median of -$15.2 million in 2015.
  • Biggest five-year swings in Deferred Taxes: crashed 3964.41% in 2016 and later soared 39.5% in 2017.
  • Year by year, Deferred Taxes stood at -$989000.0 in 2015, then plummeted by 3964.41% to -$40.2 million in 2016, then skyrocketed by 39.5% to -$24.3 million in 2017, then skyrocketed by 82.39% to -$4.3 million in 2018, then plummeted by 195.68% to -$12.7 million in 2019.
  • Business Quant data shows Deferred Taxes for ABUS at -$12.7 million in Q3 2019, -$4.3 million in Q3 2018, and -$24.3 million in Q4 2017.